cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF^V600E mutation

Acta Neuropathol. 2019 Apr;137(4):683-687. doi: 10.1007/s00401-019-01987-0. Epub 2019 Mar 8.

David W Ellison¹, Cynthia Hawkins², David T W Jones^{3

4}, Arzu Onar-Thomas⁵, Stefan M Pfister^{3

6}, Guido Reifenberger⁷, David N Louis⁸

¹ Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. David.Ellison@stjude.org.
² Division of Pathology, The Hospital for Sick Children, Toronto, Canada.
³ Hopp-Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
⁴ Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
⁵ Department of Biostatistics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
⁶ Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
⁷ Institute of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
⁸ Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.

No abstract available